Lothar Bergmann

Address Department of Internal Medicine II
J.W. Goethe University Frankfurt


Lothar Bergmann

Prof. Lothar Bergmann graduated in medicine at the J.W. Goethe University Frankfurt in 1976. He was trained in internal medicine and in 1988 admitted as a specialist in haematology and medical oncology. From 1987 he acted as Assistant Medical Director of the Department of Internal Medicine III at the University in Frankfurt. From 1997 to 1999 he served as a Provisional Professor and Medical Director at the Department of Internal Medicine at the University in Ulm, and until 2007 as a Provisional Professor and Medical Director at the Department of Internal Medicine II at the J.W. Goethe University in Frankfurt. Since August 2007, he has served at the same department as Deputy Medical Director.

Prof. Bergmann is a Chair of the Cancer Centre Rhein-Main e.V. and chairs the Haematology/Oncology section of the University Cancer Centre (UCT) Frankfurt. In addition, he is a permanent member of the Scientific Advisory Group Oncology (SAG - Oncology) of the European Medicines Agency. Prof. Bergmann chairs the Interdisciplinary Study Group for Renal Cell Cancer of the German Cancer Society (DKG). He serves as a reviewer for various national and international medical journals.

Prof. Bergmann is a member of many international societies such as the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the European Society for Medical Oncology (ESMO), the European Haematology Association (EHA), the International Society for Experimental Haematology (ISEH), and the American Society of Haematology (ASH). Additionally, he is a member of various German societies including the German Society of Haematology and Oncology (DGHO), the German Cancer Society (DKG), the Study Group for Medical Oncology (AIO), and the German Society of Internal Medicine.

Clinically he focuses on the therapies of lymphomas and chronic lymphatic leukaemias and various solid tumours as well. Scientifically he deals with tumour-suppressor genes and oncogene regulation, apoptosis in cancer cells, and immune regulation, in which the blocking of signal transduction via gene silencing and targeted agents plays a major role.